Menu

California-based Exelixis, a specialty manufacturer with two high-priced drug products on the market, announced it is further restricting contract pharmacy access to 340B hospitals in a May 31 letter published on 340B ESP.

Sobi Becomes 34th Drugmaker to Implement Contract Pharmacy Restrictions, Exelixis Tightens Contract Pharmacy Policy

June 6, 2024 Shannon Young, Managing Editor 340B Report Views

Swedish biopharmaceutical company Sobi announced this week that beginning July 1 it will implement 340B contract pharmacy restrictions, making the [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!

If you are not yet a paid subscriber, please Subscribe now

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Shannon Young

In Key Hearing, GOP Lawmakers Raise Concerns About 340B Growth and Hospital Use While Democrats Urge Caution

BMS Requires Re-Designation of 340B Contract Pharmacies and New Requirements Intended to Prevent Alternative Distribution Models